MedTrace Logo

Celebrex and Metformin for Postoperative Hepatocellular Carcinoma

NCT03184493 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2019-05-31

No results posted yet for this study

Summary

This prospective trial aims to compare the role of celebrex alone, metformin alone, and celebrex plus metformin in preventing HCC recurrence after hepatic resection.

Conditions

Interventions

DRUG

Celebrex plus Metformin

This group patients will receive metformin and celebrex.

DRUG

Celebrex

This group patients will receive celebrex.

DRUG

Metformin

This group patients will receive metformin.

Sponsors & Collaborators

  • Guangxi Medical University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-02
Primary Completion
2020-12-31
Completion
2021-06-30

Countries

  • China

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03184493 on ClinicalTrials.gov